Congleton Jon 4

What Happened

• Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold 15,730 shares in an open‑market transaction on April 13, 2026. The weighted‑average price was $26.83 per share, for total proceeds of approximately $421,979. This transaction is a sale (not a purchase).

Key Details

• Transaction date: 2026-04-13; Filing date: 2026-04-15 (filed within the typical two-business-day Form 4 window).
• Price: weighted‑average $26.83; reported trade prices ranged from $26.81 to $26.96.
• Shares sold: 15,730; proceeds: ~$421,979.
• Post‑transaction holdings: Not specified in the information provided here—see the Form 4 filing for exact beneficial ownership after the sale.
• Footnotes: Transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted December 30, 2025. The filer can provide a breakdown of shares sold at each price within the reported range upon request.

Context

• A 10b5‑1 plan indicates the trades were made under a prearranged trading plan, which is commonly used to allow insiders to sell shares on a scheduled basis and to avoid timing trades based on nonpublic information. This entry documents a routine insider sale; it does not by itself indicate the insider’s view of the company’s prospects. For full details (including post‑transaction ownership and exact per‑trade breakdown), consult the official Form 4 (Accession 0001933414-26-000075).